Overview
Octant Bio develops tools and services for next-generation medicine by applying synthetic biology and high-throughput chemistry to map how genetic information causes disease. It designs engineered genes, reporters, genetic circuits, and human cell lines, then uses nanomole-scale chemical synthesis to explore huge chemical spaces and a multiplexed assay platform to test thousands of inputs in human cells, producing millions of outputs. The company combines advanced statistics, machine learning, and bioinformatics to analyze results and accelerate decision-making, differentiating itself by tightly integrating genetic engineering, chemical space exploration, and large-scale screening with in-house capabilities. Its goal is to monetize this technology through licensing, product sales, and services that help translate complex-disease research into therapies for patients.
Work here?Claim your company
Simplify's take
What believers are saying
- First patient dosed in OCT-980 Phase 1b/2 on September 24, 2026.
- Orphan designation brings seven-year exclusivity potential and FDA development incentives.
- OpenADMET funding expands proprietary datasets, strengthening future discovery and licensing leverage.
What critics are saying
- OCT-980 clinical failure would gut the company’s only visible near-term value driver.
- Bristol Myers Squibb collaboration leaves Octant exposed to partner priorities and program selection.
- The platform remains pre-commercial; no product sales exist if OCT-980 misses efficacy endpoints.
What makes Octant Bio unique
- Octant pairs human-cell synthetic biology with generative chemistry and AI/ML.
- OCT-980 reached Phase 1b/2 and won FDA Orphan Drug Designation on October 27, 2026.
- Its OpenADMET program secured $34.8 million across three awards on September 30, 2026.
Help us improve and share your feedback! Did you find this helpful?
Funding
Industry standards